Flagship Pioneering and Pfizer partner to accelerate development of innovative medicines targeting unmet needs
- Details
- Category: Pfizer
![Pfizer Pfizer](/images/logo/pfizer.png)
AstraZeneca announces $400 million investment in reforestation and biodiversity in support of climate action and human health
- Details
- Category: AstraZeneca
![AstraZeneca AstraZeneca](/images/logo/astrazeneca.png)
AbbVie secures positive CHMP opinion for atogepant for the preventive treatment of adults with migraine
- Details
- Category: AbbVie
![AbbVie AbbVie](/images/logo/abbvie.png)
Bayer extends partnership with Peking University to foster pharmaceutical innovation in China
- Details
- Category: Bayer
![Bayer Bayer](/images/logo/bayer.png)
The collaboration will focus on selected key areas of interests, such as oncology, cardiorenal, immunology, as well as cell and gene therapy.
FDA approves Pfizer's NGENLA™, a long-acting once-weekly treatment for pediatric growth hormone deficiency
- Details
- Category: Pfizer
![Pfizer Pfizer](/images/logo/pfizer.png)
Bayer's new pharmaceutical R&D strategy to accelerate breakthrough innovations
- Details
- Category: Bayer
![Bayer Bayer](/images/logo/bayer.png)
FDA accepts Pfizer's application for hemophilia B gene therapy fidanacogene elaparvovec
- Details
- Category: Pfizer
![Pfizer Pfizer](/images/logo/pfizer.png)
More Pharma News ...
- FDA approves Pfizer's LITFULO™ (ritlecitinib) for adults and adolescents with severe alopecia areata
- Pfizer's TALZENNA® in combination with XTANDI® receives U.S. FDA approval
- Real-world evidence highlights the urgent need to act on the growing global burden of chronic kidney disease
- Bayer to acquire exclusive license from Cedilla Therapeutics on selective inhibitors in pre-clinical precision oncology
- AstraZeneca announces agreement with Quell Therapeutics to develop, manufacture and commercialise engineered T-regulatory cell therapies for autoimmune diseases
- Bayer strengthens gene therapy portfolio with lipid nanoparticle technology from Acuitas Therapeutics
- New England Journal of Medicine publishes results from Phase 3 induction and maintenance programs evaluating upadacitinib (RINVOQ®) in Crohn's disease